RxDoctor Payments DataLook up a doctor →

Justin Thomas, MD

Medical Oncology · Bozeman, MTNPI 1104002195

Payments from drug & device makers

$964,644in general payments, 2019–2025

Across 296 payments — averaging $3258.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$578K
  • Pfizer$201K
  • AstraZeneca$182K
  • Johnson & Johnson$1K
  • AbbVie$657
  • Lilly USA, LLC$253
  • plus $2K from 23 others

What the payments were for

  • Consulting fees$2,26526%
  • Travel & lodging$2,60030%
  • Food & beverage$3,79643%
  • Education$1261%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$119,987
Medicare patients
343
Services billed
1,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide32$440,627
IbrancePalbociclib25$401,921
ImbruvicaIbrutinib22$381,325
Lenalidomide28$226,293
VenclextaVenetoclax23$209,713
TagrissoOsimertinib Mesylate11$207,925
JakafiRuxolitinib Phosphate13$181,141
LynparzaOlaparib11$116,686
TasignaNilotinib Hcl11$115,439
Abiraterone Acetate30$35,517
CreonLipase/Protease/Amylase12$21,083
EliquisApixaban19$18,349
XareltoRivaroxaban15$14,805
Anastrozole63$1,259
Prochlorperazine Maleate55$987

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$200,694$420,27044 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$132$381,32522 claims
AstraZenecaTagrisso, Lynparza$181,663$324,61122 claims
AbbVieVenclexta, Creon$657$230,79735 claims
Incyte CorporationJakafi$19$181,14113 claims
NovartisTasigna$78$115,43911 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$112$35,51730 claims
Johnson & JohnsonXarelto$1,491$14,80515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Bozeman

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →